Trial Profile
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare; Bayer HealthCare Pharmaceuticals Inc.
- 25 Jul 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 29 Nov 2012 Planned end date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 17 Jul 2012 Planned End Date changed from 1 Jul 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.